Trial Profile
A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions
- 27 Jul 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2022 Planned End Date changed from 3 Jun 2022 to 15 Dec 2022.
- 21 Apr 2022 Planned primary completion date changed from 3 Jun 2022 to 15 Sep 2022.